eGenesis president and CEO Michael Curtis spoke with Forbes about recent kidney program updates.
Published
Signal category
Presence & Recognition
Quote
“Thanks Forbes for speaking with our president and CEO Michael Curtis about our recent kidney program updates.”
— eGenesis team
Company
eGenesis
Restoring life after organ failure.
- Industry
- Biotechnology Research
- Location
- Cambridge, US
- Company size
- 154 employees
eGenesis is revolutionizing the field of transplantation with an unparalleled, multiplexed gene editing platform for the development of human-compatible organs, tissues and cells. Harnessing the latest gene-editing techniques, eGenesis’ mission is to solve the global organ shortage crisis by developing a scalable alternative to allotransplantation. eGenesis is reinvigorating the field of xenotransplantation by addressing the key virology and immunology hurdles that have prevented its advancement to date, and is developing commercially-viable products to save and improve the lives of patients who are waiting for an organ transplant.
Founded 2015